![Pauline Jen Ryan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pauline Jen Ryan
Corporate Officer/Principal bij OCULAR THERAPEUTIX, INC.
Actieve functies van Pauline Jen Ryan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
OCULAR THERAPEUTIX, INC. | Corporate Officer/Principal | - | - |
Red Sky Partners LLC | Corporate Officer/Principal | 01-07-2014 | - |
Loopbaan van Pauline Jen Ryan
Eerdere bekende functies van Pauline Jen Ryan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Verik Bio, Inc. | Algemeen Directeur | 01-04-2012 | 01-11-2017 |
PROTEOSTASIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01-10-2007 | 01-08-2011 |
IMMUNOGEN, INC. | Corporate Officer/Principal | 01-05-1999 | 26-07-2007 |
Opleiding van Pauline Jen Ryan
Northwestern University | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 8 |
Operationeel
Corporate Officer/Principal | 4 |
Undergraduate Degree | 1 |
Chief Executive Officer | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
OCULAR THERAPEUTIX, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
ImmunoGen, Inc.
![]() ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Red Sky Partners LLC | |
Verik Bio, Inc. | |
Proteostasis Therapeutics, Inc.
![]() Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Pauline Jen Ryan
- Ervaring